Form 4: Heron Therapeutics CEO Craig Collard Reports Stock Unit Vesting

Heron Therapeutics CEO Craig Collard reports the vesting of 62,500 restricted stock units into common stock on April 3, 2024.

Summary

• Craig Collard, CEO of Heron Therapeutics, reported a transaction involving restricted stock units.
• On April 3, 2024, 62,500 restricted stock units vested, converting into common stock.
• Following the transaction, Collard directly owns 248,996 shares of common stock and 187,500 restricted stock units.
• The restricted stock units vest in four equal annual installments beginning one year after the grant date, contingent upon continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a routine disclosure of stock unit vesting. It reflects standard executive compensation practices.

Positives

• The vesting of restricted stock units aligns the CEO's interests with those of the shareholders.

Future Outlook

The remaining restricted stock units will continue to vest in equal annual installments over the next three years, subject to continued service.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in company stock. This filing indicates the CEO's continued holding of company stock and stock units.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time to incentivize long-term performance.
• The vesting schedule of four equal annual installments is a common practice in the industry.
• Comparing Collard's holdings and vesting schedule to those of CEOs at comparable biotech companies would provide further context.

Stakeholder Impact

• The vesting of stock units could have a minor dilutive effect on existing shareholders.

Key Dates